Bone morphogenetic protein 2 (BMP2) has been used to induce bone regeneration by promoting osteogenic differentiation of MSCs.5, 6 However, extended clinical use of BMP has revealed its transient and low osteo-inductive efficacy in vivo.7, 8 The molecular mechanism of abnormal endogenous MSCs fate determination remains elusive, which hinders the progress of osteoporosis treatment. Here, BMP2 is linked to osteoporosis.